Member Info for martinu

Kibo not a great partner choice, to say the least. MNRG still have a bit to prove too. Even Wood who have tech and expertise, have a lot of debt.

Eqtec, who need partners to provide funds, etc have not made some good decisions. Presumably they are not spoilt for choice though.

PS: So the source which mentioned payment terms of sometimes 9 months or even a year was the recent IG video,mainly about Probiotix. When talking about large retail partners.

From memory, in a recent interview, SOH mentioned payment terms (to Opti). If I am not mistaken, he indicated these could be as generous as 12 months. Though hopefully this would be for very few contracts. Can't remember source, but if true won't help cash-flow in short term.

He has said in the past that NHS is difficult to deal with. Apparently not for Novo Nordisk, the Danish company who own this drug.

https://www.bbc.co.uk/news/health-64874243

Mja - a very good question, as often it's the potential revenue that is highlighted. I can't answer your question, but the extract below relating to Italia MDC might give a clue for a small plant.

"The Parties, excluding the Company, have jointly committed to and have now paid an aggregate €2.1m for an 80% equity interest, with the Company holding the remaining 20% equity interest in the SPV for a capital contribution of €482,000"

And as with all construction related projects, costs often rise substantially by completion.

PS: Come on guys, get a "bleddy" (Devon swear word) RNS out on Italia MDC. And if it's a (further) delay, just be honest and get it out there.

Happy, you are a real comfort :) But it had (has? ) come to the point where it is a bit of a race against time. Get a working project up and running v running out of cash.

Suppose the fact that Eqtec themselves are recommisioning some previously failed plants was an indicator of difficulties with businesses model.

Well and truly back down to earth today. But in spite of my doubting tone, I still have fingers crossed. Which would be an honest opening to an RNS advertising further delay; of which I hope there isn't any.

"CEO DP says, Yoel and the team have their fingers crossed that Italia MDC will be fully operational by xxx" :)

What made me smile was that we got 2 RNSs today. Not quite what we were hoping for but I'll take the SP rise.

In some ways, it is a shame the likely very good news of Italia MDC will come out so close to any Deeside update.

Aandi's link:

http://www.alignresearch.co.uk/metalnrg/metalnrg-back-to-work-full-time-on-the-corporate-strategy/

https://youtu.be/sen9YAG9gMo

Thanks to posters who shared this.

SOH as positive as ever. Thinks Steen can really drive sales in PBX. And restates his view that PBX will be a takeover target in a couple of years. Also says, movement from Aquis to AIM is cheaper after 18 months. Is that from now or from 1st listing? Assume former?

We shall see.

SOH as positive as ever. Thinks Steen can really drive sales in PBX. And restates his view that PBX will be a takeover target in a couple of years. Also says, movement from Aquis to AIM is cheaper after 18 months. Is that from now or from 1st listing? Assume former?

We shall see.

To date it seems easier to make the negative case. Mostly this is due to debt, dilution and deadlines missed.

The positive case (below) is currently less tangible. In (my) order of "tangibility".

1. Italia MDC - working manually, we are told but not yet under auto-control.
2. Croatia MDC - some components manufactured, but not yet fully financed.
3. North Fork MDC - progress resumed, but uncertainty over Eqtec equity after bankruptcy filing.
4. Greece MDC - quiet since 2021
5. France - good tie up with University and positive governmental environment.

This is mainly from memory, so if anyone wishes to correct detail, happy to hear it.

Whilst Eqtec apparently have reined in costs, it seems to me it is still a struggle between cash flow (to put it mildly) and converting (even one) of the small MDCs to regain credibility. Cheers. MU.

AS, this is from the half year report in Sep 22.

"The listing of PBX on AQSE means that PBX is now considered an associate for accounting purposes with its revenues and costs removed post listing and only OptiBiotix's (44%) proportion of its profit and loss included in the Company's accounts. This makes year on year comparisons challenging."

I am definitely not an accountant, so am unclear what this will mean for FY. Prelims or otherwise.

I presume (hope) so too. Preliminary (unaudited) figures last year were released on 28th Feb. Revenues were £2.2m. About half and half for pre-and probiotix. We know prebiotix bombed in H1.

Extract from last Feb

"Total invoiced sales for the Group were £2.2m (2020: £1.5m) an increase of 46.7% on the previous year..."

Accounting might be "messy" with Probiotix separation.

Well, Eqt have produced biochar successfully. Who needs the syngas? ;)

ErsteSahne (1st cream?), the problem for "investors" like me is that, I like the idea behind the company, but I don't really know much detail about how the tech works and how long it takes to complete stages on the way to successful completion. So I would prefer regular communication from the company. Especially around the Italia MDC, as this is absolutely key to selling Eqtec to prospective, large scale funders. Viel Glück.

Try spohara@optibiotix.com

For me, better the devil you know, for the time being. But, the pipeline would be more relevant and the CEO's credibility enhanced, by completion of projects in a timely fashion.

Perhaps disappointingly then, this was from update on 9th Feb 22 (almost a year to the date) :

"Investor update: The Company has increased its investor activity with the re-engagement of Proactive Investors, the continued use of the Investor Meet Company for more substantive news, and positive features in The Daily Mail and This is Money."